Biotech Values

[genisi]

What's interesting about ABT is they are the dark horse in this contest. They are behind in development, with a somewhat sloppy combination, yet 90%+ SVR rates is a remarkable achievement even within this small study.

What I like about ABT is they are doing a very thorough work testing multiple combos of all three MoA (PI, non-nuke, NS5A inhibitor, and +/-Riba) for all the drugs they have in all the subgroups (genotypes, IL28b, prior treatments).